Weight-Loss Pill by Wegovy Makers Shows 13% Weight Reduction in Phase 1 Trials

Wednesday, 11 September 2024, 15:21

Weight-loss pill by Wegovy makers, amycretin, has successfully reduced body weight by up to 13% in initial trials. This exceeds weight loss results from Wegovy. Presenting data at the European Association for the Study of Diabetes, Novo Nordisk revealed significant findings that highlight amycretin's potential effectiveness and safety, comparable to existing GLP-1 medications.
LivaRava_Medicine_Default.png
Weight-Loss Pill by Wegovy Makers Shows 13% Weight Reduction in Phase 1 Trials

The Efficacy of Amycretin in Weight Loss

Novo Nordisk, the renowned maker of Ozempic and Wegovy, has announced promising results from its early Phase 1 clinical trial of the experimental weight-loss pill, amycretin. After three months, participants experienced an impressive weight reduction of up to 13%. This finding significantly surpasses the approximate 6% weight loss documented by those on Wegovy during a similar timeframe.

Key Findings from the Trial

  • Amycretin demonstrated both safety and tolerability, with side effects akin to those expected from other GLP-1 medications.
  • Common side effects reported were nausea, vomiting, diarrhea, and constipation.
  • The mechanism of action for amycretin includes functioning as both a GLP-1 and amylin receptor agonist, influencing appetite and blood sugar levels.

Amycretin Versus Existing Treatments

The distinct pharmacological mechanism of amycretin, the daily oral dosage, is believed to provide greater appeal compared to Wegovy's weekly injection format.

For more information regarding this promising drug, please visit the source for further details.


This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Subscribe to our newsletter for the most accurate and current medical news. Stay updated and deepen your understanding of medical advancements effortlessly.

Subscribe